Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$17.4M
5M shares
52-week range
$1.79 – $24.00
8% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
223.66%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $68.0K | $185.0K | $0 | $0 | $0 | $0 | $0 | $90.0K |
| Gross profit | −$68.0K | −$185.0K | $0 | $0 | $0 | $0 | $0 | −$90.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $9.7M | $11.0M | $12.8M | $14.4M | $19.0M | $19.5M | $17.7M | $15.9M |
| Operating income | −$15.0M | −$17.5M | −$19.7M | −$23.0M | −$30.6M | −$29.6M | −$26.6M | −$25.1M |
| EBITDA | −$15.0M | −$13.2M | −$19.5M | −$15.7M | −$28.9M | −$29.6M | −$21.6M | −$33.5M |
| Net income | −$11.9M | −$13.2M | −$17.4M | −$15.9M | −$29.0M | −$29.8M | −$21.8M | −$33.6M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1031.54 | -729.63 | -661.00 | -221.77 | -380.51 | -376.71 | -189.14 | -28.42 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $71M | $-5.11 | $-5.60–$-4.61 | 1 |
| 2027 | $42M | $-3.84 | $-4.41–$-3.26 | 2 |
| 2028 | $87M | $-3.56 | $-4.83–$-2.28 | 2 |
| 2029 | $52M | $0.96 | $0.96–$0.96 | 1 |
Forward consensus · source: Financial Modeling Prep
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
www.moleculin.comNo one on the platform currently holds MBRX.
No tracked institution reports a position in MBRX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-12-01 | 1-for-25reverse |
| 2024-03-22 | 1-for-15reverse |
| 2021-02-01 | 1-for-6reverse |
No one on the platform has traded MBRX yet.
| $27M |
| — |
| BLRXBioLineRx Ltd. | $3.10 | -2.05% | $13M | — |
| CTXRCitius Pharmaceuticals, Inc. | $0.58 | +7.15% | $6M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$MBRX Sell the news as sooon as it drops. They stil need 2 more quarters worth of runway to complete part A, if part A is not allowed, the trial extends until 2029 for primary completson. Since inception 15,705$ stock price has turned into 3.54$. They will need to raise capital and there is a huige ATM out with Jefferies, expect them to sell the news to fund operations! My takke.
View on StockTwits ↗$MBRX so what will we see tonight after the close - an Update on the trial or a secondary offering
View on StockTwits ↗$MBRX what could the price of the stock once the data is out historical context would help
View on StockTwits ↗$MBRX Analysts and experts are very optimistic about their 2B/3 Miracle trial results and so am I. Expecting a nice pop once the positive data is out.
View on StockTwits ↗$MBRX I feel like a lot of those from $SLS are hopping over here to MBRX and helping this price action. Sadly MBRX has garbage finances but the modelling work is similar to Sellas where you can calculate above 90% chance of success off unblinded data.
View on StockTwits ↗$MBRX Well, Wally did say an update in June, so Weds. is July 1st. Maybe we will get a halt for the news? Cheers-
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.